MENTAL RETARDATION, AUTOSOMAL DOMINANT 36
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
|
26168268 |
2015 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 36
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Large-scale discovery of novel genetic causes of developmental disorders.
|
25533962 |
2015 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 36
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
|
26168268 |
2015 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 36
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
MENTAL RETARDATION, AUTOSOMAL DOMINANT 36
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
MENTAL RETARDATION, AUTOSOMAL DOMINANT 36
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Intellectual Disability
|
0.400 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Large-scale discovery of novel genetic causes of developmental disorders.
|
25533962 |
2015 |
Intellectual Disability
|
0.400 |
Biomarker
|
group |
HPO |
|
|
|
Ovarian clear cell carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Mutation of PPP2R1A has been observed at high frequency in endometrial serous carcinomas but at low frequency in ovarian clear cell carcinoma.
|
27272709 |
2016 |
Ovarian clear cell carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Exome sequencing of ovarian clear-cell carcinoma has identified somatic mutations in PPP2R1A, a subunit of protein phosphatase 2A.
|
21435433 |
2011 |
Ovarian clear cell carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
The other two mutated genes were previously unknown to be involved in OCCC: PPP2R1A encodes a regulatory subunit of serine/threonine phosphatase 2, and ARID1A encodes adenine-thymine (AT)-rich interactive domain-containing protein 1A, which participates in chromatin remodeling.
|
20826764 |
2010 |
Ovarian clear cell carcinoma
|
0.330 |
CausalMutation
|
disease |
CGI |
|
|
|
Malignant neoplasm of stomach
|
0.300 |
Biomarker
|
disease |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
Degenerative polyarthritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
Osteoarthrosis Deformans
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Restoration of wild-type PPP2R1A in P179R-mutant endometrial cancer cells increases phosphatase activity and inhibits tumor growth <i>in vivo</i> Furthermore, a small-molecule activator of PP2A (SMAP) phenocopies restoration of wild-type PPP2R1A to suppress tumor growth.
|
31416848 |
2019 |
Adenocarcinoma of prostate
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Colorectal Neoplasms
|
0.100 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, overexpression of PPP2R1A-WT increased cell proliferation in vitro and tumor growth in vivo.
|
27272709 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Multivariate analysis showed that larger tumor size, higher mitotic rate, and PPP2R1A mutation are independent prognostic factors for overall survival; however, PPP2R1A mutation was not an independent prognostic factor for disease-free survival.
|
27469332 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, overexpression of the Aα mutants in EC cells harboring wild-type PPP2R1A increased anchorage-independent growth and tumor formation, and triggered hyperphosphorylation of oncogenic PP2A-B56/B' substrates in the GSK3β, Akt, and mTOR/p70S6K signaling pathways.
|
27485451 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |